

## New submissions:

<b>Palforzia<sup>®</sup></b>	<b>Not yet classified</b>	<ul style="list-style-type: none"> <li>Treating peanut allergy in children and young people.</li> <li>As per <a href="#">NICE TA769</a>.</li> <li>Local treatment pathway will be developed (may require referral to tertiary care).</li> </ul>
<b>Bevespi<sup>®</sup></b> <b>Aerosphere pMDI</b> (glycopyrronium bromide/formoterol fumarate dihydrate 7.2 µg/5.0 µg )	<b>AMBER 3</b>	<ul style="list-style-type: none"> <li>Licensed as a maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD).</li> <li>A dual fixed-dose LAMA/LABA combination in a pMDI device.</li> <li>The recommended dose is two inhalations twice daily.</li> </ul>
<b>Trixeo<sup>®</sup></b> <b>Aerosphere pMDI</b> (formoterol fumarate/ glycopyrronium/ budesonide 5/7/160µg)	<b>GREY</b>	<ul style="list-style-type: none"> <li>Moderate to severe COPD in adult patients.</li> <li>No advantage over the current triple MDI inhaler choice.</li> </ul>
<b>Trurapi<sup>®</sup> - insulin aspart biosimilar</b>	<b>AMBER 2</b>	<ul style="list-style-type: none"> <li>Offers significant cost savings compared to Novorapid<sup>®</sup></li> <li>Prescribe by brand.</li> <li>First-line insulin aspart product for new patients.</li> <li>Available as cartridges, prefilled pens and 10ml vials.</li> <li>The pre-filled pen device is the Solostar, which is the same device used for Lantus<sup>®</sup> (insulin glargine).</li> </ul>

## APC webinars - new

A pre-recorded APC update webinar is now available to view for [March 2022](#).

## News from the APC - updated/new documents:

### [Allergic Rhinoconjunctivitis Guideline](#) - update

- Added note to consider montelukast for asthmatic patients who also have rhinitis.
- Highlighted benefit of nasal douching and added patient information with instructions.
- Highlighted importance of correct nasal spray technique - [link to video](#).
- Added advice to purchase eye drops.
- Consider higher dose antihistamines (off licence) with counselling about drowsiness and driving.
- More detailed referral information.

### [Ciclosporin Eye Drops Information Sheet](#) **Ikervis<sup>®</sup> (adults) & Verkazia<sup>®</sup> (ages 4-17)** - update

- Combined Ikervis<sup>®</sup> and Verkazia<sup>®</sup> information sheets into one.
- Highlighted important of counselling patients on risks of driving if vision is blurred.
- Avoid in pregnancy and if breast feeding.
- Ikervis<sup>®</sup> interaction added for pomelo and purple grape juice.
- Prescribe by brand.

### [Acute Cough / Bronchitis Guideline](#) - update

- In previously healthy patients most cases of acute bronchitis are associated with a viral infection.
- The majority of coughs are self-limiting and will resolve in 3-4 weeks without antibiotics.
- Self-care strategies and links to TARGET and APC patient information leaflets added.
- Guidance on when to consider offering an antibiotic added.
- Guidance on when to consider offering an antibiotic after a CRP test added.

## News from the APC continued - updated/new documents:

### [Clonidine for Tics Information Sheet](#) - new

- Prescribing information sheet to support traffic light change from RED to AMBER 2 for tics and tic disorders in children.
- Includes information on dose, dose titration, monitoring requirements and responsibilities, duration of treatment, criteria for review, and interactions.

### [CCG Preferred Prescribing List](#) - update

Preferred cost effective brands / formulations for new prescribing in primary care in Nottinghamshire

- Now more cost effective to prescribe metformin MR generically.
- Remember to prescribe lidocaine 5% plasters as Ralvo brand.
- Omeprazole dispersible tablets (Mezzopram brand) only to be used if opening capsules (licensed) is not possible.
- Controlled drugs preferred brands under review (with risk assessment) - no changes at present.

### [Shared Care Patient Information Leaflet](#) - new

- Answers some frequently asked questions about shared care.
- Written for patients and/or carers.

## Horizon scanning, formulary amendments and traffic light changes

- **Antimicrobials for acne** - **AMBER 3** in line with APC antimicrobial guidelines (previously Green or Amber 2).
- **Atropine 1% eye drops preservative free Minims** - clarified as **AMBER 2**, for hypersalivation.
- **Chloral hydrate and chloral betaine** - clarified as **RED** for short term sleep disorders and **AMBER 2**, for patients with movement disorders or sleep problems associated with a movement disorder.
- **Clonidine** - **AMBER 2** classification for tic disorders in children.
- **Fexofenadine 30mg film-coated tablets** - added as **GREEN** for paediatric use.
- **GnRH analogues** - clarified that triptorelin is first line for gender dysphoria (remains **AMBER 2**). Leuprorelin and goserelin are second line for gender dysphoria (**AMBER 2**).
- **Hydrogen Peroxide 3% Solution BP** - clarified as **AMBER 2**.
- **Methadone tablets and liquid** - **AMBER 2**, classification to be expanded to include initiation by the palliative team.
- **Methadone 10mg/ml solution for injection** - deferred to DTC for consideration of **RED**.
- **Minoxidil 5% scalp foam (Regaine®)** - clarified as **GREY** (available to buy over the counter).
- **Nirmatrelvir / ritonavir (Paxlovid®▼)** - added to formulary as **RED**.
- **Orlistat** - **GREY** (was Amber 3), less suitable for prescribing and GPs not commissioned to provide weight management service. To be reviewed if tier 3 weight management service is commissioned.
- **Potassium Permanganate (Permitabs®)** - clarified as **AMBER 2** on wound care specialist recommendation.
- **Venlafaxine oral solution**— added as **GREEN**. Oral solution is very expensive, consider alternative antidepressants first if a liquid formulation is indicated.
- **IM Pabrinex®** - **AMBER 3** (was Amber 2). A 15-minute observation period is recommended post injection due to a very small risk of anaphylaxis and facilities for treating anaphylaxis should be available. See the primary care [alcohol dependence guideline](#) for more information.

## Current work in development— see [APC work programme](#) for further details

- Type 2 diabetes guideline (update)
- Sick day rules and SGLT2s (new)
- Growth Hormone SCP (update)
- Anticoagulants for NVAf Guideline (update)
- Aminosalicylates in IBD (new)
- Antimicrobial guidelines (update)
- Overarching Pain Management Guideline (new)
- Vitamin B12 Treatment Guideline (update)
- Vitamin D Guideline for Adults (update)
- Thyroid replacement in pregnancy (new)
- Transgender collaborative care protocol and information sheets (new)